AbbVie (NYSE: ABBV) has been ordered to pay $150 million to a patient who claimed that the US drugmaker hid the risks of its AndroGel testosterone booster in aggressive advertising campaigns.
Oregon man Jesse Mitchell argued that the company misled him and his doctor about AndroGel’s propensity for causing blood clots that can lead to heart attacks. Mr Mitchell suffered a heart attack in 2012, having taken AndroGel for four years.
AbbVie denied the claims, though sales of its testosterone booster have reduced since regulators put more severe label warnings on the product in 2015.
The jury in the Chicago federal court found on Monday that AbbVie was not liable for Mr Mitchell’s heart attack but awarded him the punitive damages on the basis of fraudulent misrepresentation.
AbbVie’s share price finished 0.9% down on Monday, at $73.91.